Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)
China · Delayed Price · Currency is CNY 10.31
+0.08 (0.78%)
Feb 3, 2026, 3:00 PM CST
SHA:600267 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 9,620 | 9,572 | 10,158 | 11,709 | 11,902 | 11,011 |
Other Revenue | 215.22 | 215.22 | 215.53 | 328.14 | 234.07 | 343.88 |
| 9,835 | 9,787 | 10,373 | 12,037 | 12,136 | 11,354 | |
Revenue Growth (YoY) | 3.02% | -5.65% | -13.82% | -0.82% | 6.89% | 2.55% |
Cost of Revenue | 5,370 | 5,644 | 6,338 | 7,119 | 7,331 | 6,547 |
Gross Profit | 4,465 | 4,143 | 4,035 | 4,918 | 4,806 | 4,807 |
Selling, General & Admin | 2,947 | 3,000 | 3,258 | 3,431 | 3,453 | 3,396 |
Research & Development | 467.21 | 357.69 | 391.95 | 428.69 | 372.8 | 401.15 |
Other Operating Expenses | 77.73 | 52.03 | 45.6 | 111.62 | 111.52 | 80.09 |
Operating Expenses | 3,609 | 3,496 | 3,719 | 3,962 | 3,950 | 3,836 |
Operating Income | 856.48 | 646.81 | 316.55 | 956.29 | 855.41 | 970.95 |
Interest Expense | -111.1 | -155.9 | -215.4 | -283.12 | -345.81 | -420.75 |
Interest & Investment Income | 7.53 | 191.79 | 89.22 | 51.57 | 121.41 | 66.95 |
Currency Exchange Gain (Loss) | 2.67 | 2.67 | 3.42 | -0.58 | -4.79 | -19.93 |
Other Non Operating Income (Expenses) | -23.11 | 0.29 | -2.86 | -5.55 | -2.34 | -4.33 |
EBT Excluding Unusual Items | 732.48 | 685.66 | 190.94 | 718.61 | 623.88 | 592.89 |
Gain (Loss) on Sale of Investments | -72.6 | -14.93 | 0.28 | -135.77 | -17.77 | 0.73 |
Gain (Loss) on Sale of Assets | 0.04 | -0.56 | -55.24 | -2.06 | -46.71 | 29.26 |
Asset Writedown | 21.62 | -2.84 | -149.46 | -0.57 | -2.24 | -0.26 |
Other Unusual Items | 50.75 | 50.75 | -69.38 | 103.22 | 87.03 | 281.52 |
Pretax Income | 732.29 | 718.07 | -82.87 | 683.42 | 644.19 | 904.14 |
Income Tax Expense | 183.2 | 126.76 | 14.15 | 192.19 | 133.56 | 180.97 |
Earnings From Continuing Operations | 549.08 | 591.31 | -97.01 | 491.23 | 510.63 | 723.17 |
Minority Interest in Earnings | -2.29 | 9.87 | 3.84 | -2.37 | -23.74 | -305.97 |
Net Income | 546.8 | 601.18 | -93.17 | 488.86 | 486.89 | 417.19 |
Net Income to Common | 546.8 | 601.18 | -93.17 | 488.86 | 486.89 | 417.19 |
Net Income Growth | - | - | - | 0.40% | 16.71% | 348.25% |
Shares Outstanding (Basic) | 1,152 | 1,166 | 1,165 | 1,164 | 1,132 | 970 |
Shares Outstanding (Diluted) | 1,152 | 1,166 | 1,165 | 1,164 | 1,132 | 970 |
Shares Change (YoY) | -1.52% | 0.13% | 0.06% | 2.80% | 16.71% | 4.24% |
EPS (Basic) | 0.47 | 0.52 | -0.08 | 0.42 | 0.43 | 0.43 |
EPS (Diluted) | 0.47 | 0.52 | -0.08 | 0.42 | 0.43 | 0.43 |
EPS Growth | - | - | - | -2.33% | - | 330.00% |
Free Cash Flow | 1,966 | 1,876 | 1,263 | 1,535 | 1,114 | 897.57 |
Free Cash Flow Per Share | 1.71 | 1.61 | 1.08 | 1.32 | 0.98 | 0.93 |
Dividend Per Share | 0.210 | 0.210 | - | 0.170 | 0.140 | 0.050 |
Dividend Growth | - | - | - | 21.43% | 182.26% | -0.80% |
Gross Margin | 45.40% | 42.34% | 38.90% | 40.86% | 39.60% | 42.34% |
Operating Margin | 8.71% | 6.61% | 3.05% | 7.95% | 7.05% | 8.55% |
Profit Margin | 5.56% | 6.14% | -0.90% | 4.06% | 4.01% | 3.67% |
Free Cash Flow Margin | 19.99% | 19.17% | 12.17% | 12.75% | 9.18% | 7.90% |
EBITDA | 1,947 | 1,714 | 1,353 | 1,985 | 1,797 | 1,845 |
EBITDA Margin | 19.80% | 17.52% | 13.04% | 16.49% | 14.81% | 16.25% |
D&A For EBITDA | 1,091 | 1,067 | 1,036 | 1,029 | 941.92 | 874.34 |
EBIT | 856.48 | 646.81 | 316.55 | 956.29 | 855.41 | 970.95 |
EBIT Margin | 8.71% | 6.61% | 3.05% | 7.95% | 7.05% | 8.55% |
Effective Tax Rate | 25.02% | 17.65% | - | 28.12% | 20.73% | 20.02% |
Revenue as Reported | 9,835 | 9,787 | 10,373 | 12,037 | 12,136 | 11,354 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.